Amgen Inc. (NASDAQ: AMGN) along with Zai Lab (NASDAQ: ZLAB) announced the completion of the final analysis of the Phase 3 FORTITUDE-101 trial for bemarituzumab with chemotherapy in first-line gastric cancer. The pre-specified interim analysis revealed that the bemarituzumab plus chemotherapy regimen showed a substantial improvement in overall survival compared to chemotherapy alone. However, at the final analysis, the initial survival benefit observed has decreased in magnitude. Amgen plans to present the results at an upcoming medical meeting. For detailed information, visit Benzinga.com.